710012

[illegible]	[illegible]
ACCESSION NO.	[illegible]
TITLE	PION RADIOTHERAPY AT LAMPF
AUTHORS	[illegible], S.[illegible]; SMITH, A.R.; ZINK, S.
AUTHOR AFF	UNIV. OF NEW MEXICO, ALBUQUERQUE
PUB DESC	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY AND PHYSICS (U.S.)--, V. 8, NO. 12, PP. 2181-2186
TYP	J
JOURNAL CODEN	IOBPD
DATE	DEC 1982
PUBLISHER CODE	0360-3016
CO OF AUTH	US
CO OF PUBL	US
ANN J	INS-84:007[illegible]; EDB-84:058098
DOCUMENT ORIGIN	P
DIS	JA1
CATEGORIES	EDB-560151;550603
PRIMARY CAT	EDB-560151(BIOMEDICAL SCIENCES, APPLIED STUDIES; RADIATION EFFECTS; MAN)
SEC SECTION	C1500;C[illegible]
ABSTRACT	CLINICAL INVESTIGATIONS OF PI MESON RADIOTHERAPY WERE CONDUCTED BY THE CANCER RESEARCH AND TREATMENT CENTER OF THE UNIVERSITY OF NEW MEXICO AND THE LOS ALAMOS NATIONAL LABORATORY FROM 1974 UNTIL 1982. TWO HUNDRED AND THIRTY PATIENTS HAVE BEEN TREATED FOR A VARIETY OF LOCALLY ADVANCED PRIMARY AND METASTATIC NEOPLASMS. ONE HUNDRED AND NINETY-SIX PATIENTS HAVE BEEN FOLLOWED FOR A MINIMUM OF 18 MONTHS. CRUDE SURVIVAL DATA RANGE FROM 11% FOR UNRESECTABLE PANCREATIC CARCINOMA TO 82% FOR STAGES C AND D1 ADENOCARCINOMA OF THE PROSTATE. ACUTE TOLERANCE OF NORMAL TISSUES IS APPROXIMATELY 4500 PION RAD IN 5[illegible] FRACTIONS OVER 7 WEEKS. SEVERE CHRONIC REACTIONS HAVE APPEARED WITH INCREASING FREQUENCY AFTER DOSES IN EXCESS OF 4000 PION RAD.
DESCRIPTORS	*PIONS MINUS--EVALUATION; *RADIOTHERAPY--SIDE EFFECTS; CARCINOMAS,LAMPF LINAC,PANCREAS,PATIENTS,PROSTATE;SURVIVAL TIME
ISSUE	[illegible]
UNPOSTED DESC	ACCELERATORS;BODY,[illegible]SONS,DIGESTIVE SYSTEM,DISEASES;ELEMENTARY PARTICLES,ENDOCRINE GLANDS;GLANDS;HADRONS,LINEAR ACCELERATORS; MALE GENITALS,MEDICINE,MESON FACTORIES;MESONS;NEOPLASMS;NUCLEAR MEDICINE,ORGANS,PIONS;PSEUDOSCALAR MESONS;RADIOLOGY;THERAPY
DOCUMENT NO	84:058098

1066974

DOE/HQ